摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline | 516526-37-7

中文名称
——
中文别名
——
英文名称
4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline
英文别名
4-{[7-(benzyloxy)-6-methoxy-4-quinazolinyl]oxy}aniline;4-((7-(Benzyloxy)-6-methoxyquinazolin-4-yl)oxy)aniline;4-(6-methoxy-7-phenylmethoxyquinazolin-4-yl)oxyaniline
4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline化学式
CAS
516526-37-7
化学式
C22H19N3O3
mdl
——
分子量
373.411
InChiKey
KGFPAXKAUHJGHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    575.0±50.0 °C(Predicted)
  • 密度:
    1.280±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    79.5
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline2-(4-异丙基-1H-1,2,3-三唑-1-基)乙酸N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以72%的产率得到N-(4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)phenyl)-2-(5 isopropyl-1H-1,2,3-triazol-1-yl)acetamide
    参考文献:
    名称:
    [EN] PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER
    [FR] COMPOSÉS DE PHÉNOXYQUINALZOLINE ET LEUR UTILISATION EN TRAITEMENT D'UN CANCER
    摘要:
    这项发明涉及Formula (I)的化合物或其药学上可接受的盐,其中R1、R2、R3和R4具有在描述中先前定义的任何含义;它们的制备方法,含有它们的药物组合物以及它们在治疗KIT介导疾病中的用途。
    公开号:
    WO2018197643A1
  • 作为产物:
    描述:
    对氨基苯酚7-苄氧基-4-氯-6-甲氧基喹唑啉 在 sodium hydride 作用下, 以 二甲基亚砜 、 mineral oil 为溶剂, 反应 1.17h, 以91%的产率得到4-((7-(benzyloxy )-6-methoxyquinazolin-4-yl)oxy)aniline
    参考文献:
    名称:
    [EN] PHENOXYQUINAZOLINE COMPOUNDS AND THEIR USE IN TREATING CANCER
    [FR] COMPOSÉS DE PHÉNOXYQUINALZOLINE ET LEUR UTILISATION EN TRAITEMENT D'UN CANCER
    摘要:
    这项发明涉及Formula (I)的化合物或其药学上可接受的盐,其中R1、R2、R3和R4具有在描述中先前定义的任何含义;它们的制备方法,含有它们的药物组合物以及它们在治疗KIT介导疾病中的用途。
    公开号:
    WO2018197643A1
点击查看最新优质反应信息

文献信息

  • Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
    申请人:Miwa Atsushi
    公开号:US20050049264A1
    公开(公告)日:2005-03-03
    An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR 10 , CR 11 R 2 , carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R 1 to R 3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R 4 represents H; R 5 to R 8 each independently represent H, halogen, alkyl, or alkoxy; and R 9 represents an optionally substituted carbocyclic or heterocyclic group.
    本发明的目标是提供新型化合物,其具有对FGF受体家族自磷酸化的抑制活性,并在口服或静脉注射时能够抑制癌细胞的生长。本发明的化合物由公式(I)或其药学上可接受的盐或溶剂表示:其中X代表CH或N; Z代表O或S; Q代表NR10,CR11R2,羰基,O,S(═O)m,其中m为0到2,或脲基; R1至R3各自独立地表示H、OH、卤素、硝基、氨基、烷基、烷氧基或其类似物,其中烷基和烷氧基基团可选择性地被取代; R4表示H; R5至R8各自独立地表示H、卤素、烷基或烷氧基; R9表示一个可选择性取代的碳环或杂环基团。
  • Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
    申请人:Miwa Atsushi
    公开号:US20080207617A1
    公开(公告)日:2008-08-28
    An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.
    本发明的目标是提供化合物和药物,用于治疗抑制FMS样酪氨酸激酶3(Flt3)自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物,用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病,所述药物组合物包括以下公式(I)所表示的化合物或其药学上可接受的盐或溶剂:其中X代表CH或N;Z代表O或S;R1、R2和R3代表H、OH或可选取代的烷氧基;R4代表H;R5、R6、R7和R8代表H、卤素、烷基或类似物;R9代表例如被t-丁基或类似物取代的烷基。
  • QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
    申请人:KIRIN BEER KABUSHIKI KAISHA
    公开号:EP1447405A1
    公开(公告)日:2004-08-18
    An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents 0 or S; Q represents NR10, CR11R12, carbonyl, O, S(=O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.
    本发明的目的是提供对 FGF 受体家族的自身磷酸化具有抑制活性的新型化合物,口服或静脉注射后可抑制癌细胞的生长。本发明的化合物由式(I)或其药学上可接受的盐或溶液表示: 其中 X 代表 CH 或 N;Z 代表 0 或 S;Q 代表 NR10、CR11R12、羰基、O、S(=O)m(其中 m 为 0 至 2)或脲;R1 至 R3 各自独立地代表 H、OH、卤素、硝基、氨基、烷基、烷氧基或类似基团,其中烷基和烷氧基是任选取代的;R4 代表 H;R5 至 R8 各自独立地代表 H、卤素、烷基或烷氧基;R9 代表任选取代的碳环或杂环基团。
  • Phenoxyquinazoline compounds and their use in treating cancer
    申请人:AstraZeneca AB
    公开号:US11053223B2
    公开(公告)日:2021-07-06
    The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation, pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    本发明涉及式(I)化合物:或其药学上可接受的盐,其中 R1、R2、R3 和 R4 具有本文在描述中定义的任何含义;其制备工艺、含有它们的药物组合物及其在治疗 KIT 介导的疾病中的用途。
  • Carbamate and urea compounds as multikinase inhibitors
    申请人:ANGEX PHARMACEUTICAL, INC.
    公开号:US11358949B2
    公开(公告)日:2022-06-14
    The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.
    本公开描述了作为新型多激酶抑制剂的氨基甲酸酯和脲化合物及其制备方法。还描述了包含这种多激酶抑制剂的药物组合物以及使用它们治疗癌症、传染病和其他与激酶有关的疾病的方法。
查看更多